Ligand Pharmaceuticals (LGND) Equity Income (2015 - 2020)

Ligand Pharmaceuticals has disclosed Equity Income across 6 years of filings, most recently posting -$25.5 million for Q1 2020.

• Equity Income for Q1 2020 came in at -$25.5 million, down 247.2% year-over-year; the trailing twelve-month figure through Mar 2020 was -$39.9 million (down 192.66% YoY), and the FY2019 annual result was $2.9 million, down 93.94% from the prior year.
• Equity Income came in at -$25.5 million for Q1 2020 at Ligand Pharmaceuticals, down from $8.5 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $59.9 million in Q3 2018 to a low of -$74.0 million in Q4 2018.
• The 5-year median for Equity Income is -$1.2 million (2017), against an average of $180705.9.
• Peak annual rise in Equity Income reached 5975.47% in 2018, while the deepest fall reached 1758.18% in 2018.
• Ligand Pharmaceuticals' Equity Income stood at -$9.0 million in 2016, then surged by 149.64% to $4.5 million in 2017, then slumped by 1758.18% to -$74.0 million in 2018, then soared by 111.46% to $8.5 million in 2019, then sank by 400.19% to -$25.5 million in 2020.
• The last three Equity Income figures came in at -$25.5 million (Q1 2020), $8.5 million (Q4 2019), and -$10.5 million (Q3 2019), per Business Quant data.